Carcinoembryonic Antigen | CMS Coverage Update

Summary: The Centers for Medicare & Medicaid Services modified its coverage policy for carcinoembryonic antigen (CEA) testing, effective May 15, 2026. Here's what billing teams need to do.

CMS CEA coverage policy changes affect labs, oncology practices, and gastroenterology groups that bill Medicare for tumor marker testing. The policy does not carry a numbered policy code in the standard NCD or LCD format. This post covers what the modification means for your claims, what medical necessity documentation you need, and what to do before the effective date of May 15, 2026.

CMS Carcinoembryonic Antigen Coverage Criteria and Medical Necessity Requirements 2026

The CMS carcinoembryonic antigen coverage policy governs when Medicare will pay for CEA testing. The full source document for this modification is available at app.payerpolicy.org. Because no detailed policy summary was included in the data feed for this version, the criteria below reflect CMS's established coverage framework for CEA — the framework this modification builds on.

CEA is a tumor marker. Medicare covers CEA testing when it is medically necessary for managing a patient's known malignancy. The key word is "managing." Medicare does not cover CEA as a screening tool in average-risk patients.

Medical necessity for CEA billing generally requires a confirmed diagnosis of a CEA-producing cancer — most commonly colorectal, lung, breast, medullary thyroid, or pancreatic carcinoma. Your documentation must show the test is being ordered to monitor treatment response, detect recurrence, or evaluate disease progression. A physician order alone is not enough. The medical record must support the clinical rationale.

CMS evaluates medical necessity at the claim level and at audit. If your documentation shows CEA was ordered pre-operatively as a baseline, that carries coverage — but only when a malignancy is already established. Ordering CEA to rule out cancer in a patient with no confirmed diagnosis is the claim denial pattern CMS auditors look for most often. That distinction belongs front and center in your intake and order workflows.

Prior authorization is not typically required by CMS for CEA testing under Medicare Part B. However, your Medicare Administrative Contractor (MAC) may have issued a local coverage determination (LCD) that adds criteria or restricts coverage in your region. Check with your MAC before assuming national policy is the only standard that applies.

Reimbursement for CEA testing runs through the Medicare Clinical Laboratory Fee Schedule. The fee schedule rate is set nationally, but MAC-level LCDs can restrict the clinical indications that support payment. A CEA claim that meets the national CMS coverage policy criteria can still deny at the MAC level if the diagnosis codes don't align with the local LCD.

CMS CEA Testing Exclusions and Non-Covered Indications

CMS does not cover CEA testing in several situations. These are the denial drivers your billing team needs to know cold.

Screening in average-risk patients. CEA has no proven value as a cancer screening tool. CMS does not cover CEA ordered for general population screening, wellness visits, or routine checkups in patients without a confirmed malignancy.

Monitoring benign conditions. CEA levels can be elevated in non-malignant conditions — smoking, cirrhosis, inflammatory bowel disease. Medicare will not pay for CEA ordered solely to monitor these conditions unless an underlying malignancy is also documented.

Diagnostic workup without a confirmed cancer diagnosis. If a physician orders CEA to investigate an unexplained mass or elevated symptom burden before a cancer diagnosis is established, that claim will not meet medical necessity under the CMS coverage policy. The confirmed diagnosis must precede — or be concurrent with — the CEA order.

Frequency beyond clinical need. CMS does not set a hard numeric limit on CEA frequency in its national policy, but your MAC's LCD may. Repeated testing without documented clinical justification — particularly at intervals shorter than treatment or surveillance cycles warrant — is a common audit target.

If any of these patterns appear in your current CEA billing, pull a sample of recent claims now. Don't wait until after May 15, 2026.

Coverage Indications at a Glance

The policy data for this modification does not include a structured indications list with code-level detail. The table below reflects CMS's established CEA coverage framework.

CMS Carcinoembryonic Antigen Billing Guidelines and Action Items 2026

The modification is effective May 15, 2026. These are the steps your billing and RCM teams should take now.

CPT, HCPCS, and ICD-10 Codes for Carcinoembryonic Antigen Under This Policy

The policy data for this modification does not list specific CPT, HCPCS, or ICD-10 codes. Do not rely on this post as a code reference for claim submission.

What to Do Instead

Your billing team should take three steps to confirm the correct codes for CEA billing under Medicare.

First, check the Medicare Clinical Laboratory Fee Schedule on the CMS website. CEA testing has a specific CPT code and an associated fee schedule allowable. That code and rate are your ground truth for charge capture.

Second, search your MAC's LCD database by procedure name ("carcinoembryonic antigen") or by the CPT code you currently use. The LCD will list the covered ICD-10-CM diagnosis codes that support medical necessity. If your diagnosis codes aren't on that list, the claim will deny.

Third, review your current charge description master (CDM) entry for CEA. Confirm the CPT code, revenue code (if applicable for hospital outpatient billing), and any attached modifier are current and consistent with your MAC's requirements.

Publishing specific codes here without confirmation from the policy document itself would create more risk than clarity for your team. Use the CMS source document at app.payerpolicy.org/p/cms/118-v1 as your authoritative reference for this modification.